CCCC – c4 therapeutics, inc. (US:NASDAQ)

News

C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com